Biotech Strategy

🇺🇦 Biotech Strategy Blog provides commentary on #pharma #biotech new product development with focus on #oncology #ImmunoOnc #tcellrx (sub req'd)

[Sally Church @MaverickNY]

Ten abstracts which caught our eye and raised some eyebrows at #ESMO26.

Not everything which blooms is quite as rosy as it first appears when put in the spotlight... https://t.co/YmRzrB0HJu

[Sally Church @MaverickNY]

The KRAS G12D race is becoming increasingly competitive, with several companies already running phase 3 trials.

In our latest red and green flag analysis, we explore whether Verastem's strategy with VS-7375 will help or hinder: https://t.co/zjUbNsMJvs

[Sally Church @MaverickNY]

A quick take on the Genmab epcoritamab announcement in 1L DLBCL – are we conquering aggressive lymphomas and improving outcomes for patients? https://t.co/UvTrSzFgPe

[Sally Church @MaverickNY]

Ten experiments and the shape of things to come: a look at 10 early stage developments to watch out for at #ESMO26 and what issues you need to pay attention to:
https://t.co/B9EekRKLbg

[Sally Church @MaverickNY]

All aboard the #ESMO26 train! Before everyone heads off to Madrid, it's time for our annual Preview series to begin.

In the first one we look at the big picture and what trends are emerging this year: https://t.co/0sUPLOh52c

[Sally Church @MaverickNY]

Don't miss the signal! 10 ways in which novel cancer targets could emerge over the next decade:

https://t.co/GD0s9afv35

[Biotech Strategy @BiotechStrategy]

Our latest analysis and commentary from #wclc26

[Sally Church @MaverickNY]

We have come far in lung cancer in terms of progress, yet there's still a long way to go.
In our latest review we discuss some of the challenges coming out of Seoul for iza-bren, sac-TMT, and T-DXd in NSCLC:
https://t.co/BJvZCIWLrj

[Sally Church @MaverickNY]

There's a lot to learn beyond the impressive B7-H3 ADC showing in 2L SCLC #WCLC26.

Here's a dozen reasons why you should look more carefully beyond the OS data at the datasets for Ris-Rez and Tam-Peli:

https://t.co/cwpfvQdSya

[Sally Church @MaverickNY]

Can targeted drugs make better ADC payloads, especially when there's no cytotoxic involved? A few companies are exploring this concept in the clinic already.

We've been exploring how some new directions could go either way: https://t.co/EL6FwyM6Bm

[Sally Church @MaverickNY]

With #WCLC26 coming up, it's a good time to talking about therapeutic index (TI) and how companies are making it wider in the context of novel ADCs: https://t.co/kiwk7A3wwW

[Sally Church @MaverickNY]

After a brief summer break, we're back with some in-depth analysis and discussion. This one's on the AZN volrustomig data in 1L NSCLC and what factors might explain the miss:

https://t.co/8hWqIxms7d

[Sally Church @MaverickNY]

With pipeline changes and plenty of clues to follow, are the EGFRxMET bispecifics and ADCs going up, up, and away?

Check out our latest analysis to find out: https://t.co/ukok6ItA2Y

[Sally Church @MaverickNY]

Looking at GSK/Hansoh's ris-rez in SCLC – the holes tell us where the big questions lie... a critique of the latest B7-H3 ADC data and what to watch out for:

https://t.co/VATyIW51JL

[Sally Church @MaverickNY]

People always love intriguing data with a plot twist (or two) in the tail and this review highlights several key angles to watch out for.
So just who's the apple of some productive researchers' eye?
https://t.co/5fByQ6TzA5

[Sally Church @MaverickNY]

Sometimes when mired in a morass of data you have to stop and face the dragon. For companies developing ADCs, this moment may be coming sooner than many realise:
https://t.co/BTUz5bRhDZ

[Sally Church @MaverickNY]

Exploring a new IO wave to see who might have some staying power versus who might be heading for the rocks: https://t.co/nLIaxJpoKl

[Sally Church @MaverickNY]

When it comes to new ideas, the myeloma niche is full of them w/ plenty of new regimens to explore. Some are breaking new ground, others may be left behind before they get going.

We discuss five promising ones, including an unexpected sleeper option:

https://t.co/8q4b6Wx6fD

[Sally Church @MaverickNY]

AML progress is no illusion, neither are the traps. Where we offer some highlights and challenges in this disease – who's standing out from the crowd?

https://t.co/diy8xqziQr

[Sally Church @MaverickNY]

Roche just paid $700M upfront for a BTK degrader this month. We're not sure the patient population it needs will still exist by the time it reaches the market.
Our #EHA26 take: https://t.co/rGZO904wcU

[Sally Church @MaverickNY]

Keeping a beady eye on the data. Time to apply the Feuerstein-Ratain rule to a clinical readout from #ASCO26 – a specific use case with a stark reminder:

https://t.co/42HZx6wAjJ